Phathom Pharmaceuticals Overview

  • Founded
  • 2019
  • Status
  • Public
  • Employees
  • 55
  • Stock Symbol
  • PHAT
Stock Symbol
  • Share Price
  • $34.99
  • (As of Friday Closing)

Phathom Pharmaceuticals General Information


Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Stock Exchange
Primary Office
  • 2150 East Lake Cook Road
  • Suite 800
  • Buffalo Grove, IL 60089
  • United States
+1 (877) 000-0000

Phathom Pharmaceuticals Timeline

Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Phathom Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$34.99 $35.04 $28.10 - $50.78 $1.1B 31.3M 94K -$4.20

Phathom Pharmaceuticals Financials Summary

In Thousands,
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 832,583 758,010 807,112
Revenue 0 0 0 0
EBITDA (138,794) (125,255) (252,035) (1,275)
Net Income (143,770) (129,068) (255,131) (1,288)
Total Assets 246,363 295,111 257,178 902
Total Debt 49,296 49,018 23,573 1,950
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Phathom Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Phathom Pharmaceuticals‘s full profile, request access.

Request a free trial

Phathom Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Terrie Curran Chief Executive Officer & Board Member
Todd Branning Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Azmi Nabulsi MD Founder & Chief Operating Officer, Operations
Martin Gilligan Chief Commercial Officer
Eckhard Leifke MD Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Phathom Pharmaceuticals Board Members (10)

Name Representing Role Since
David Socks Phathom Pharmaceuticals Founder & Board Member 000 0000
Heidi Kunz Phathom Pharmaceuticals Board Member 000 0000
Mark Stenhouse Self Board Member 000 0000
Michael Cola Self Board Member 000 0000
Tadataka Yamada MD Self Chairman & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Phathom Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial